Feb 25, 2015 9:04 am EST Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies
Jan 23, 2015 9:04 am EST Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
Nov 6, 2014 10:00 am EST Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch
Jun 18, 2014 9:04 am EDT Lixte's Lead Compound LB-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer
Apr 25, 2013 9:00 am EDT Lixte Biotechnology Announces Initiation Of A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
Nov 27, 2012 9:00 am EST Lixte Biotechnology Holdings Announces New Appointment To Board Of Directors
Jul 31, 2012 9:00 am EDT Lixte Biotechnology Holdings Announces Increased Funding And FDA Allowance To Conduct A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
May 1, 2012 12:00 pm EDT Lixte Biotechnology Holdings Announces Submission of an IND to the FDA for Approval of a Clinical Trial of LB-100, a First-in-Class, Anti-Cancer Compound
Apr 4, 2012 9:30 am EDT Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor